bucindolol (Incara/SkyePharma)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namebucindolol (Incara/SkyePharma)
Drug Alias Namebucindololbucindolol (Incara/Jago)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor antagonistsBeta-1 adrenergic receptor degraders
TargetsBeta-2 adrenergic receptorBeta-1 adrenergic receptor
Therapy Area/IndicationsHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAeolus Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJago Pharma AGAeolus Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsHypertension

Other Information

ATC CodeN/A
Related LinksN/A